Evidence map›Paper›PMID 37490204›Full record

ReviewStem cell reviews and reports2023

The Current Proceedings of PSC-Based Liver Fibrosis Therapy.

Li Ma, Qiang Wu, Paul Kwong-Hang Tam

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Stem cell reviews and reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Li MaThe State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, China.
Qiang WuThe State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, China. qwu@must.edu.mo.ORCID 0000-0003-2049-1639
Paul Kwong-Hang TamFaculty of Medicine, Macau University of Science and Technology, Taipa, China. pkhtam@must.edu.mo.
Macau University of Science and Technology · MO

Funding

FDCT 0072/2019/A2
6 · The paper itself

Abstract

Liver fibrosis was initially considered to be an irreversible process which will eventually lead to the occurrence of liver cancer. So far there has been no effective therapeutic approach to treat liver fibrosis although scientists have put tremendous efforts into the underlying mechanisms of this disease. Therefore, in-depth research on novel and safe treatments of liver fibrosis is of great significance to human health. Pluripotent stem cells (PSCs) play important roles in the study of liver fibrosis due to their unique features in self-renewal ability, pluripotency, and paracrine function. This article mainly reviews the applications of PSCs in the study of liver fibrosis in recent years. We discuss the role of PSC-derived liver organoids in the study of liver fibrosis, and the latest research advances on the differentiation of PSCs into hepatocytes or macrophages. We also highlight the importance of exosomes of PSCs for the treatment of liver fibrosis.

Indexed as

Liver CirrhosisPluripotent Stem CellsAnimalsCell DifferentiationExosomesHepatocytesHumansOrganoidsExosomesLiver fibrosisOrganoidsPluripotent stem cells (PSCs)

Identifiers

PMID37490204
OpenAlexW4385231101

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.